Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry

Cardiovascular Revascularization Medicine

Volumn 13, Issue 3, 2012, Pages 159-166

  Stellbaum, Caroline ^a   Ayral, Yunus ^a   Morguet, Andreas ^a   Schultheiss, Heinz Peter ^a   Rauch, Ursula ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Clopidogrel; Impedance aggregometry; Low responder; VASP phosphorylation

Indexed keywords

ADENOSINE DIPHOSPHATE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTAGLANDIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; IMPEDANCE; IMPEDANCE AGGREGOMETRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTRIC IMPEDANCE; FEMALE; FLOW CYTOMETRY; GERMANY; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; P-SELECTIN; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; RECEPTORS, THROMBIN; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84861670767     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2012.02.009     Document Type: Article

References (33)

1. Geiger J., Teichmann L., Grossmann R., Aktas B., Steigerwald U., Walter U., et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005, 51(6):957-965.
2. Piorkowski M., Weikert U., Schwimmbeck P.L., Martus P., Schultheiss H.P., Rauch U. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost 2004, 92:614-620.
3. Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by Monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003, 59(3):295-302.
4. Vila P.M., Zafar M.U., Badimon J.J. Platelet reactivity and nonresponse to dual antiplatelet therapy: a review. Platelets 2009, 20:531-538.
5. Armero A., Camoin Jau L., Omar Ait Mokhtar O., Mancini J., Burignat-Bonello C., Tahirou I., et al. Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. Platelets 2010, 21:503-507.
6. Geisler T., Langer H., Wydymus M., Göhring K., Zürn C., Bigalke B., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006, 27(20):2420-2425.
7. Pampuch A., Cerletti C., de Gaetano G. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006, 96:767-773.
8. Bouman H.J., Parlak E., van Werkum J.W., Breet N.J., ten Cate H., Hackeng C.M., et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010, 8:482-488.
9. Rauch U., Ziegler D., Piolot R., Schwippert B., Benthake H., Schultheiss H.P., et al. Platelet activation in diabetic cardiovascular autonomic neuropathy. Diabet Med 1999, 16(10):848-852.
10. Stellbaum C., Willich T., Boltzen U., Ayral Y., Szotowski B., Piorkowski M., et al. Clopidogrel-mediated reduction of circulating tissue factor in patients with stable coronary artery disease. Eur J Haematol 2007, 78:347-352.
11. Weikert U., Kühl U., Schultheiss H.P., Rauch U. Platelet activation is increased in patients with cardiomyopathy: myocardial inflammation and platelet reactivity. Platelets 2002, 13:487-491.
12. Tschoepe D., Schultheiss H.P., Kolarov P., Schwippert B., Dannehl K., Nieuwenhuis H.K., et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993, 88:37-42.
13. Siller-Matula J.M., Christ G., Lang I.M., Delle-Karth G., Huber K., Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010, 8:351-359.
14. Geiger J., Brich J., Honig-Liedl P., Eigenthaler M., Schanzenbacher P., Herbert J.M., et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999, 19:2007-2011.
15. Aleil B., Ravanant C., Cazenave J.P., Rochoux G., Heitz A., Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular disease. J Thromb Haemost 2005, 3(1):85-92.
16. Michelson A.D. Methods for the measurement of platelet function. Am J Cardiol 2009, 103(3 Suppl):20A-26A.
17. Sibbing D., Braun S., Morath T., Mehilli J., Vogt W., Schömig A., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009, 53:849-856.
18. Sibbing D., Morath T., Braun S., Stegherr J., Mehilli J., Vogt W., et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010, 103(1):151-159. [Epub 2009 Oct 26].
19. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109(25):3171-3175.
20. Mueller T., Dieplinger B., Poelz W., Calatzis A., Haltmayer M. Utility of whole blood impedance aggregometry fort the assessment of clopidogrel action using the novel Multiplate analyzer-comparison with two flow cytometric methods. Thromb Res 2007, 121:249-258.
21. Hezard N., Metz D., Garnotel R., Simon G., Mace C., Koebel P., et al. phosphorylation assessment in clopidogrel-treated patients: lack of agreement between Western blot and flow cytometry. Platelets 2005, 16(8):474-481.
22. Calatzis A, Loreth R, Spannagl M. Multiplate® platelet function analysis-application and interpretation. Multiplate® compendium.
23. Geisler T., Gawaz M. Variable response to clopidogrel in patients with coronary artery disease. Semin Thromb Hemost 2007, 33(2):196-202.
24. Jaster M., Horstkotte D., Willich T., Stellbaum C., Knie W., Spencker S., et al. The amount of fibrinogen-positive platelets predicts the occurrence of in-stent restenosis. Atherosclerosis 2008, 197:190-196.
25. Graff J., Klinkhardt U., Schini-Kerth V.B., Harder S., Franz N., Bassus S., et al. Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor. J Pharmacol Exp Ther 2002, 300(3):952-957.
26. von Beckerath N., Sibbing D., Jawansky S., Braun S., Morath T., Vogt W., et al. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry. Blood Coagulation and Fibrinolysis 2010, 21:46-52.
27. Velik-Salchner C., Maier S., Innerhofer P., Streif W., Klingler A., Kolbitsch C., et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth Analg 2008, 107(6):1798-1806.
28. Rauch U., Crandall J., Osende J.I., Fallon J.T., Chesebro J.H., Fuster V., et al. Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. Am J Cardiol 2000, 86(2):246-249.
29. Price M.J., Berger P.B., Angiolillo D.J., Teirstein P.S., Tanguay J.F., Kandzari D.E., et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design a rationale of the GRAVITAS trial. Am Heart J 2009, 157:818-824.
30. Piorkowski M., Fischer S., Stellbaum C., Jaster M., Martus P., Morguet A.J., et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone is sufficient cholesterol-lowering enough to inhibit platelets?. J Am Coll Cardiol 2007, 49:1035-1042.
31. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007, 49:2312-2317.
32. Spinler S.A., Rees C. Review of prasugrel for the secondary prevention of atherothrombosis. J Manag Care Pharm 2009, 15(5):383-395.
33. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.